AP2007003891A0 - Quinazolin-4-yl-piperidine and cinnolin-4-yl-pipe ridine derivatives as pde10 inhibitors for the treatment of cns disorders - Google Patents
Quinazolin-4-yl-piperidine and cinnolin-4-yl-pipe ridine derivatives as pde10 inhibitors for the treatment of cns disordersInfo
- Publication number
- AP2007003891A0 AP2007003891A0 AP2007003891A AP2007003891A AP2007003891A0 AP 2007003891 A0 AP2007003891 A0 AP 2007003891A0 AP 2007003891 A AP2007003891 A AP 2007003891A AP 2007003891 A AP2007003891 A AP 2007003891A AP 2007003891 A0 AP2007003891 A0 AP 2007003891A0
- Authority
- AP
- ARIPO
- Prior art keywords
- cinnolin
- quinazolin
- piperidine
- treatment
- cns disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59094304P | 2004-07-23 | 2004-07-23 | |
PCT/IB2005/002177 WO2006011040A1 (en) | 2004-07-23 | 2005-07-11 | Quinazolin-4-yl- piperidine and cinnolin-4-yl- piperidine derivatives as pde10 inhibitors for the treatment of cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2007003891A0 true AP2007003891A0 (en) | 2007-02-28 |
Family
ID=34972555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2007003891A AP2007003891A0 (en) | 2004-07-23 | 2005-07-11 | Quinazolin-4-yl-piperidine and cinnolin-4-yl-pipe ridine derivatives as pde10 inhibitors for the treatment of cns disorders |
Country Status (25)
Country | Link |
---|---|
US (1) | US20060019975A1 (xx) |
EP (1) | EP1773805A1 (xx) |
JP (1) | JP2008507500A (xx) |
CN (1) | CN1989124A (xx) |
AP (1) | AP2007003891A0 (xx) |
AR (1) | AR050433A1 (xx) |
AU (1) | AU2005266080A1 (xx) |
BR (1) | BRPI0513475A (xx) |
CA (1) | CA2574685A1 (xx) |
CR (1) | CR8861A (xx) |
EA (1) | EA200700097A1 (xx) |
EC (1) | ECSP077193A (xx) |
GT (1) | GT200500198A (xx) |
IL (1) | IL180205A0 (xx) |
MA (1) | MA28746B1 (xx) |
MX (1) | MX2007000878A (xx) |
NL (1) | NL1029596C2 (xx) |
NO (1) | NO20065948L (xx) |
PE (1) | PE20060570A1 (xx) |
SV (1) | SV2006002175A (xx) |
TN (1) | TNSN07021A1 (xx) |
TW (1) | TW200616641A (xx) |
UY (1) | UY29028A1 (xx) |
WO (1) | WO2006011040A1 (xx) |
ZA (1) | ZA200700223B (xx) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006039325A2 (en) * | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
CA2599688A1 (en) * | 2005-03-01 | 2006-09-08 | Wyeth | Cinnoline compounds and their use as liver x receptor modulators |
CA2635439A1 (en) * | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
WO2007098169A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
AU2007217474A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
AU2007221049A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
US20090099175A1 (en) * | 2006-03-01 | 2009-04-16 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
US20070265258A1 (en) * | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
AU2007223801A1 (en) * | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
JPWO2007119361A1 (ja) * | 2006-03-17 | 2009-08-27 | 三菱瓦斯化学株式会社 | キナゾリン−4−オン誘導体の製造方法 |
PL2057153T3 (pl) * | 2006-07-10 | 2013-01-31 | H Lundbeck As | POCHODNE (3-ARYLO-PIPERAZYN-1-YLOWE) 6,7-DIALKOKSYCHINAZOLINY, 6,7-DIALKOKSYFTALAZYNY i 6,7-DIALKOKSYIZOCHINOLINY |
EP1903038A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
EP1903037A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors |
US20090062291A1 (en) * | 2007-08-22 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
TW200918519A (en) * | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
US7858620B2 (en) * | 2007-09-19 | 2010-12-28 | H. Lundbeck A/S | Cyanoisoquinoline |
UA102693C2 (ru) | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
EP2376455B1 (en) | 2008-12-17 | 2012-11-14 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
WO2011143129A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors |
CN103221404B (zh) | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
US8497265B2 (en) | 2010-05-13 | 2013-07-30 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors |
CA2799020A1 (en) | 2010-05-13 | 2011-11-17 | Jennifer R. Allen | Heteroaryloxycarbocyclyl compounds as pde10 inhibitors |
TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
DE102010042833B4 (de) | 2010-10-22 | 2018-11-08 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung |
JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
EP2675791B1 (en) | 2011-02-18 | 2016-02-17 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
WO2013045607A1 (en) | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
AR089361A1 (es) | 2011-12-21 | 2014-08-20 | Lundbeck & Co As H | Derivados de quinolina como inhibidores de la enzima pde10a |
WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
TW201348231A (zh) | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
EP2855453B1 (en) | 2012-06-04 | 2016-12-07 | Actelion Pharmaceuticals Ltd. | Benzimidazole-proline derivatives |
WO2014057435A1 (en) | 2012-10-10 | 2014-04-17 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
CA2902135A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
JP6421185B2 (ja) | 2013-12-04 | 2018-11-07 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | ベンゾイミダゾール−プロリン誘導体の使用 |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
CN109999039A (zh) * | 2014-04-04 | 2019-07-12 | H.隆德贝克有限公司 | 作为pde1抑制剂的卤化的喹唑啉-thf-胺 |
CN106632089B (zh) * | 2016-11-04 | 2019-06-18 | 中山大学 | 一类喹唑啉类化合物及其制备方法与应用 |
JP2023504249A (ja) | 2019-11-28 | 2023-02-02 | バイエル・アクチエンゲゼルシヤフト | 免疫活性化のためのdgkアルファ阻害剤としての置換アミノキノロン類 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3517005A (en) * | 1967-10-26 | 1970-06-23 | Pfizer & Co C | Certain 2- and 4-substituted quinazolines |
GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
IN148482B (xx) * | 1977-06-03 | 1981-03-07 | Pfizer | |
JPS60120872A (ja) * | 1983-12-01 | 1985-06-28 | Kyowa Hakko Kogyo Co Ltd | 新規なヘテロ環状化合物及び強心剤 |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
CA2118117A1 (en) * | 1993-02-18 | 1994-08-19 | Shigeki Fujiwara | Adenosine uptake inhibitor |
CA2148260A1 (en) * | 1993-09-10 | 1995-03-16 | Yasutaka Takase | Quinazoline cpompounds |
JP3919272B2 (ja) * | 1996-12-18 | 2007-05-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナゾリン系化合物 |
US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
EP2048142A3 (en) * | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
JP4782564B2 (ja) * | 2002-07-10 | 2011-09-28 | メルク セローノ ソシエテ アノニム | アゾリジノン−ビニル縮合−ベンゼン誘導体 |
-
2005
- 2005-07-08 US US11/178,104 patent/US20060019975A1/en not_active Abandoned
- 2005-07-11 CN CNA2005800248487A patent/CN1989124A/zh active Pending
- 2005-07-11 EP EP05759014A patent/EP1773805A1/en not_active Withdrawn
- 2005-07-11 AP AP2007003891A patent/AP2007003891A0/xx unknown
- 2005-07-11 JP JP2007522057A patent/JP2008507500A/ja not_active Withdrawn
- 2005-07-11 EA EA200700097A patent/EA200700097A1/ru unknown
- 2005-07-11 MX MX2007000878A patent/MX2007000878A/es unknown
- 2005-07-11 CA CA002574685A patent/CA2574685A1/en not_active Abandoned
- 2005-07-11 BR BRPI0513475-7A patent/BRPI0513475A/pt not_active Application Discontinuation
- 2005-07-11 WO PCT/IB2005/002177 patent/WO2006011040A1/en active Application Filing
- 2005-07-11 AU AU2005266080A patent/AU2005266080A1/en not_active Abandoned
- 2005-07-20 PE PE2005000840A patent/PE20060570A1/es not_active Application Discontinuation
- 2005-07-21 UY UY29028A patent/UY29028A1/es not_active Application Discontinuation
- 2005-07-21 GT GT200500198A patent/GT200500198A/es unknown
- 2005-07-21 AR ARP050103018A patent/AR050433A1/es unknown
- 2005-07-22 NL NL1029596A patent/NL1029596C2/nl not_active IP Right Cessation
- 2005-07-22 TW TW094124808A patent/TW200616641A/zh unknown
- 2005-07-22 SV SV2005002175A patent/SV2006002175A/es not_active Application Discontinuation
-
2006
- 2006-12-20 IL IL180205A patent/IL180205A0/en unknown
- 2006-12-21 NO NO20065948A patent/NO20065948L/no not_active Application Discontinuation
-
2007
- 2007-01-08 ZA ZA200700223A patent/ZA200700223B/xx unknown
- 2007-01-18 CR CR8861A patent/CR8861A/es not_active Application Discontinuation
- 2007-01-22 TN TNP2007000021A patent/TNSN07021A1/fr unknown
- 2007-01-23 EC EC2007007193A patent/ECSP077193A/es unknown
- 2007-01-23 MA MA29625A patent/MA28746B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
GT200500198A (es) | 2006-03-02 |
SV2006002175A (es) | 2006-02-15 |
MX2007000878A (es) | 2007-03-12 |
TW200616641A (en) | 2006-06-01 |
ECSP077193A (es) | 2007-02-28 |
UY29028A1 (es) | 2006-02-24 |
AU2005266080A1 (en) | 2006-02-02 |
NL1029596C2 (nl) | 2006-09-06 |
EA200700097A1 (ru) | 2007-06-29 |
AR050433A1 (es) | 2006-10-25 |
US20060019975A1 (en) | 2006-01-26 |
PE20060570A1 (es) | 2006-07-14 |
EP1773805A1 (en) | 2007-04-18 |
JP2008507500A (ja) | 2008-03-13 |
BRPI0513475A (pt) | 2008-05-06 |
CA2574685A1 (en) | 2006-02-02 |
IL180205A0 (en) | 2007-07-04 |
ZA200700223B (en) | 2008-08-27 |
NL1029596A1 (nl) | 2006-01-24 |
WO2006011040A1 (en) | 2006-02-02 |
NO20065948L (no) | 2007-01-23 |
CN1989124A (zh) | 2007-06-27 |
TNSN07021A1 (fr) | 2008-06-02 |
CR8861A (es) | 2007-03-02 |
MA28746B1 (fr) | 2007-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2007003891A0 (en) | Quinazolin-4-yl-piperidine and cinnolin-4-yl-pipe ridine derivatives as pde10 inhibitors for the treatment of cns disorders | |
ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
IL180736A0 (en) | Hydantoin derivatives for the treatment of inflammatory disorders | |
IL177772A0 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
AP2334A (en) | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. | |
HK1186125A1 (en) | Quinoline derivatives for the treatment of latent tuberculosis | |
HK1199254A1 (en) | Process for the preparation of aurora kinase inhibitors | |
ME01219B (me) | Alfa-aminoamid derivati korisni u liječenju bolesti zavisnosti | |
IL179508A0 (en) | 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
EP1853295A4 (en) | METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES | |
EP1940441A4 (en) | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS | |
IL180187A0 (en) | Compositions and methods for treating inflammatory disorders | |
EP1874286A4 (en) | METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE | |
EP1644021A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
IL190201A0 (en) | Pde inhibitors and combinations thereof for the treatment of urological disorders | |
IL180680A0 (en) | Piperazine derivatives useful for the treatment of gastrointestinal disorders | |
IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
IL175610A0 (en) | Methods and reagents for the treatment of inflammatory disorders | |
EP1799258A4 (en) | METHODS FOR TREATMENT OF ANGIOGENESIS | |
IL191537A0 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
HK1121378A1 (en) | Compositions and methods for the treatment of addiction and other neuropsychiatric disorders | |
SI1831227T1 (sl) | Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj | |
EP1812009A4 (en) | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CNS | |
ZA200705160B (en) | Quinoline derivatives for the treatment of latent tuberculosis | |
EP1940379A4 (en) | METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES |